ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2023
Impact of Enterococcus faecalis Endocarditis Treatment on Risk of Relapse.
Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 61 citations in OpenAlex.
- When Less Is More: Volume Considerations in the Treatment ofOpen forum infectious diseases · 2026Article
- Low Yield of Blood Cultures After End of Therapy of an Episode of Infective Endocarditis: 12 Years' Experience From a Referral Center.Open forum infectious diseases · 2026Article
- Changing antimicrobial prescribing patterns, and laboratory reporting in Enterococcus faecalis infective endocarditis at a tertiary Australian centre.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Article
- Clinical characteristics, treatment, and outcomes in CIED-related vs. left-sided infective endocarditis: a nationwide study from the NIDUS registry.Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology · 2026Article
- Rethinking the Routine: Are Repeat Blood Cultures Necessary After Completion of Infective Endocarditis Treatment?Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026Article
- Loss of Fsr quorum sensing promotes biofilm formation and worsens outcomes in enterococcal infective endocarditis.Nature communications · 2026Article
- 16S rRNA Metabarcoding Used to Identify the Etiology of Infective Endocarditis Agents.Sovremennye tekhnologii v meditsine · 2026Article
- 2023 European Society of Cardiology guidelines for the management of infective endocarditis : Statement of endorsement by the NVVC Full version.Netherlands heart journal : monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation · 2026Review
- Dual β-lactam synergy in Enterococcus faecalis and its relationship with penicillin-ceftriaxone infective endocarditis treatment outcomes.The Journal of antimicrobial chemotherapy · 2025Article
- Article
- Comparison of ceftriaxone versus ceftaroline in combination with ampicillin or penicillin againstMicrobiology spectrum · 2025Article
- Mapping Review of the Correlations Between Periodontitis, Dental Caries, and Endocarditis.Dentistry journal · 2025Review
- Review
- Evaluation of ampicillin plus ceftobiprole combination therapy in treating Enterococcus faecalis infective endocarditis and bloodstream infection.Scientific reports · 2025Article
- Bacterial Diversity in Native Heart Valves in Infective Endocarditis.Biomedicines · 2025Article
- Combination therapy versus monotherapy: retrospective analysis of antibiotic treatment of enterococcal endocarditis.BMC infectious diseases · 2025Article
- Treatment Options for Nosocomial Ventriculitis/Meningitis: A Case Report and Review of the Literature.Pathogens (Basel, Switzerland) · 2024Review
- The emerging challenge ofClinical microbiology reviews · 2024Review
- Outcomes ofJAC-antimicrobial resistance · 2024Article
- Advancements and Challenges in the Management of Prosthetic Valve Endocarditis: A Review.Pathogens (Basel, Switzerland) · 2024Review
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
21 authors at 15 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEnterococcus faecalis infective endocarditis (EFIE) is characterized by a higher frequency of relapses than other infective endocarditis. The role of the treatment on its occurrence remains poorly understood. The aim of this study was to investigate whether the antibiotic regimen could impact the risk of relapse in EFIE. MATERIALS: This was a multicenter retrospective study of patients diagnosed with definite EFIE between 2015 and 2019 in 14 French hospitals. The primary endpoint was the occurrence of relapses within the year following endocarditis diagnosis. As death was a competing risk for relapse, Fine and Gray models were used for studying risk factors and impact of treatment.
resultsOf the 279 patients included, 83 (29.7%) received the amoxicillin-gentamicin (A-G) combination, 114 (40.9%) amoxicillin-ceftriaxone (A-C), 63 (22.6%) A-G and A-C (A-G/A-C) sequentially, 9 (3.2%) amoxicillin (A), and 10 received other treatments. One-year-relapse rate was 9.3% (26 patients). Relapse occurred after a median delay of 107 days from EFIE diagnosis; 6 occurred after 6 months, and 6 were diagnosed by blood cultures in asymptomatic patients. In multivariate analysis, surgery during treatment was a protective factor against one-year relapse and death.The cumulative incidence of relapse 1 year after endocarditis was 46.2% for patients treated with amoxicillin, 13.4% with A-G, 14.7% with A-C, and 4.3% with A-G/A-C (P≥.05 in multivariate analysis).
conclusionsRelapses after treatment of EFIE are frequent, frequently asymptomatic, and may occur more than 6 months after the initial episode.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.